Cargando…

Fixed-Dose Combination of Canagliflozin and Metformin for the Treatment of Type 2 Diabetes: An Overview

Metformin is recommended as a first-line therapy for patients with type 2 diabetes mellitus (T2DM). However, many patients do not achieve glycemic goals with metformin monotherapy and require subsequent combination therapy with other antihyperglycemic agents (AHAs). For newly diagnosed patients with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Davidson, Jaime A., Sloan, Lance
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5216068/ https://www.ncbi.nlm.nih.gov/pubmed/27854055 http://dx.doi.org/10.1007/s12325-016-0434-2

Ejemplares similares

Fixed-dose combinations in type 2 diabetes – role of the canagliflozin metformin combination
por: Fleming, Joshua W, et al.
Publicado: (2015)

Fixed-dose combination of sitagliptin and metformin for the treatment of type 2 diabetes
por: Reynolds, Jonathan K
Publicado: (2009)

Canagliflozin: Efficacy and Safety in Combination with Metformin Alone or with Other Antihyperglycemic Agents in Type 2 Diabetes
por: Qiu, Rong, et al.
Publicado: (2016)

Saxagliptin and Metformin in Fixed Combination for the Treatment of Type 2 Diabetes in Adults
por: Minze, Molly G., et al.
Publicado: (2013)

Spotlight on empagliflozin/metformin fixed-dose combination for the treatment of type 2 diabetes: a systematic review
por: Kedia, Rohit, et al.
Publicado: (2016)

Patient considerations and clinical utility of a fixed dose combination of saxagliptin/metformin in the treatment of type 2 diabetes
por: Derosa, Giuseppe, et al.
Publicado: (2011)

Adequacy of clinical trial evidence of metformin fixed-dose combinations for the treatment of type 2 diabetes mellitus in India
por: Evans, Valerie, et al.
Publicado: (2018)

Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-On to Metformin in Subjects With Type 2 Diabetes
por: Rosenstock, Julio, et al.
Publicado: (2012)

Fixed combination of repaglinide and metformin in the management of type 2 diabetes
por: Moses, Robert
Publicado: (2009)

Clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes
por: Barnard, Karen, et al.
Publicado: (2010)

Clinical utility in the treatment of type 2 diabetes with the saxagliptin/metformin fixed combination
por: Panagoulias, George S, et al.
Publicado: (2014)

Cost-Effectiveness of Canagliflozin Versus Dapagliflozin Added to Metformin in Patients With Type 2 Diabetes in China
por: Hou, Xingyun, et al.
Publicado: (2019)

Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial
por: Lavalle-González, F. J., et al.
Publicado: (2013)

Repaglinide/metformin fixed-dose combination to improve glycemic control in patients with type 2 diabetes: an update
por: Moses, Robert G
Publicado: (2010)

Safety and Efficacy of Sitagliptin-Metformin in Fixed Combination for the Treatment of Type 2 Diabetes Mellitus
por: Ballav, Chitrabhanu, et al.
Publicado: (2013)

Prolonged diabetic ketoacidosis associated with canagliflozin
por: Sloan, Gordon, et al.
Publicado: (2018)

Emerging treatments in type 2 diabetes: focus on canagliflozin
por: Rosiak, Marek, et al.
Publicado: (2014)

Canagliflozin Treatment in Patients with Type 2 Diabetes Mellitus
por: Triplitt, Curtis, et al.
Publicado: (2015)

Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin
por: Rodbard, H. W., et al.
Publicado: (2016)

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone
por: Forst, T, et al.
Publicado: (2014)

CANadian CAnagliflozin REgistry: Effectiveness and safety of canagliflozin in the treatment of type 2 diabetes mellitus in Canadian clinical practice
por: Woo, Vincent, et al.
Publicado: (2018)

Clinical Implications of Canagliflozin Treatment in Patients With Type 2 Diabetes
por: Valentine, Virginia, et al.
Publicado: (2015)

Canagliflozin: a novel treatment option for type 2 diabetes
por: Dietrich, Eric, et al.
Publicado: (2013)

Comparative Liquid Chromatographic Study for Concurrent Determination of Canagliflozin and Metformin in Combined Tablets
por: Zaghary, Wafaa A., et al.
Publicado: (2017)

Treatment Compliance with Fixed-Dose Combination of Vildagliptin/Metformin in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Metformin Monotherapy: A 24-Week Observational Study
por: Rombopoulos, Grigorios, et al.
Publicado: (2015)

Effects of canagliflozin and metformin on insulin resistance and visceral adipose tissue in people with newly-diagnosed type 2 diabetes
por: Hao, Zirui, et al.
Publicado: (2022)

Euglycemic Diabetic Ketoacidosis Accompanied by Severe Hypophosphatemia During Recovery in a Patient With Type 2 Diabetes Being Treated With Canagliflozin/Metformin Combination Therapy
por: Shoukat, Sonia, et al.
Publicado: (2017)

Sitagliptin/metformin fixed-dose combination in type 2 diabetes mellitus: an evidence-based review of its place in therapy
por: Hayes, Jennifer, et al.
Publicado: (2016)

Pioglitazone and metformin fixed-dose combination in type 2 diabetes mellitus: an evidence-based review of its place in therapy
por: Derosa, Giuseppe, et al.
Publicado: (2007)

Metformin and Canagliflozin Are Equally Renoprotective in Diabetic Kidney Disease but Have No Synergistic Effect
por: Corremans, Raphaëlle, et al.
Publicado: (2023)

Pharmacokinetic study of metformin to compare a voglibose/metformin fixed-dose combination with coadministered voglibose and metformin
por: Choi, Hyang-Ki, et al.
Publicado: (2015)

Use of Canagliflozin in Combination With and Compared to Incretin-Based Therapies in Type 2 Diabetes
por: Pratley, Richard E., et al.
Publicado: (2017)

Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial
por: Wilding, J P H, et al.
Publicado: (2013)

Evaluation of vildagliptin and fixed dose combination of vildagliptin and metformin on glycemic control and insulin dose over 3 months in patients with type 2 diabetes mellitus
por: Ved, Paresh, et al.
Publicado: (2012)

Evaluation of vildagliptin and fixed dose combination of vildagliptin and metformin on glycemic control and insulin dose over 3 months in patients with type 2 diabetes mellitus
por: Ved, Paresh, et al.
Publicado: (2013)

Evaluation of vildagliptin and fixed dose combination of vildagliptin and metformin on glycemic control and insulin dose over three months in patients with type 2 diabetes mellitus’
por: Mundra, Vishal
Publicado: (2012)

Pharmacokinetics of fixed-dose combination of atorvastatin and metformin compared with individual tablets
por: Ghim, Jong-Lyul, et al.
Publicado: (2019)

Effectiveness and safety of fixed dose combination of acarbose/metformin in Indian Type 2 diabetes patients: Results from observational GLOBE Study
por: Saboo, Banshi, et al.
Publicado: (2015)

Efficacy of glimepiride/metformin fixed-dose combination vs metformin uptitration in type 2 diabetic patients inadequately controlled on low-dose metformin monotherapy: A randomized, open label, parallel group, multicenter study in Korea
por: Kim, Hye-soon, et al.
Publicado: (2014)

Updated Review: Improved Glycemic Control with Repaglinide-Metformin in Fixed Combination for Patients with Type 2 Diabetes
por: Richard, John W., et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_so1ks1kev5ut3g3r03h1b6v87j